|
2.7 Etiologie - Obésité
|
|
|
|
3.5 Prévention - UV
|
|
|
|
4.13 Dép., diag. & prono. - Peau
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5. Traitements
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
|
|
6.1 Observation
|
|
|
|
6.11 Patients
|
|
|
|
6.6 Publications
|
|
|
Building the UK ORCID consortium [JISC]
|
|
|
|
|
|
As
well as supporting ORCID’s global project roadmap, the UK consortium
will continue to provide support to institutions to make the most of
their ORCID integrations.
|
|
|
|
|
|
|
6.7.2 Applis
|
|
|
|
6.9 Controverses
|
|
|